Comparison of two topical medications, on pain relief due to fistula cannulation in hemodialysis patients

F. Malekshahi, Shirzad Fallahi, M. Mohseni, M. Almasian
{"title":"Comparison of two topical medications, on pain relief due to fistula cannulation in hemodialysis patients","authors":"F. Malekshahi, Shirzad Fallahi, M. Mohseni, M. Almasian","doi":"10.12991/MPJ.2017.23","DOIUrl":null,"url":null,"abstract":"Patients with end stage renal failure consider the pain caused by recurrent fistula cannulations as the most intense stress they experience from their treatment and the biggest concern in their lives. One of the fundamental objectives of the nursing procedures is to relieve this pain. Therefore, this study aimed to determine the impact of two topical medications, namely Piroxicam and EMLA cream, on the pain caused by fistula cannulation among hemodialysis patients. This was a clinical trial conducted on 75 patients referring to the dialysis unit of the Shohadaye Ashayer Hospital of Khorramabad, West of Iran, in 2013. The patients were randomly divided into three groups: group A (Piroxicam), group B (EMLA cream), and group C (placebo). The data collection instrument was a questionnaire consisting of three parts: demographic information, the visual analog scale (VAS) for pain assessment, and a checklist for the likely side effects of the medications. The severity of pain during fistula cannulation was assessed in the three groups in two stages (before and after the intervention). To analyze the data, the Kruscal-Wallis and the Mann-Whitney statistical tests and SPSS 19 were used. The median for pain relief was obviously higher in the EMLA cream group than in either the Piroxicam or the placebo group and this difference was statistically significant (p<0.001). Comparing the Piroxicam and the placebo showed that the pain reduction median was much higher in the Piroxicam group than the placebo group, but the difference was not significant. The results of this study showed that the EMLA cream is more effective than the Piroxicam gel in the reduction of pain caused by fistula cannulation among hemodialysis patients. Therefore, based on the results of the present study, it can be suggested that the EMLA cream, as a simple treatment method which can be applied by the patient himself/herself, be used to relieve pain during fistula cannulation of hemodialysis patients.","PeriodicalId":18529,"journal":{"name":"Marmara Pharmaceutical Journal","volume":"129 1","pages":"1002-1009"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Marmara Pharmaceutical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12991/MPJ.2017.23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Patients with end stage renal failure consider the pain caused by recurrent fistula cannulations as the most intense stress they experience from their treatment and the biggest concern in their lives. One of the fundamental objectives of the nursing procedures is to relieve this pain. Therefore, this study aimed to determine the impact of two topical medications, namely Piroxicam and EMLA cream, on the pain caused by fistula cannulation among hemodialysis patients. This was a clinical trial conducted on 75 patients referring to the dialysis unit of the Shohadaye Ashayer Hospital of Khorramabad, West of Iran, in 2013. The patients were randomly divided into three groups: group A (Piroxicam), group B (EMLA cream), and group C (placebo). The data collection instrument was a questionnaire consisting of three parts: demographic information, the visual analog scale (VAS) for pain assessment, and a checklist for the likely side effects of the medications. The severity of pain during fistula cannulation was assessed in the three groups in two stages (before and after the intervention). To analyze the data, the Kruscal-Wallis and the Mann-Whitney statistical tests and SPSS 19 were used. The median for pain relief was obviously higher in the EMLA cream group than in either the Piroxicam or the placebo group and this difference was statistically significant (p<0.001). Comparing the Piroxicam and the placebo showed that the pain reduction median was much higher in the Piroxicam group than the placebo group, but the difference was not significant. The results of this study showed that the EMLA cream is more effective than the Piroxicam gel in the reduction of pain caused by fistula cannulation among hemodialysis patients. Therefore, based on the results of the present study, it can be suggested that the EMLA cream, as a simple treatment method which can be applied by the patient himself/herself, be used to relieve pain during fistula cannulation of hemodialysis patients.
两种外用药物缓解血液透析患者瘘管插管疼痛的比较
终末期肾衰竭患者认为复发性瘘管插管引起的疼痛是他们在治疗过程中经历的最大压力,也是他们生活中最大的担忧。护理程序的基本目标之一是减轻这种疼痛。因此,本研究旨在确定两种外用药物Piroxicam和EMLA乳膏对血液透析患者瘘管插管疼痛的影响。这是一项2013年在伊朗西部霍拉马巴德Shohadaye Ashayer医院透析病房进行的75名患者的临床试验。将患者随机分为3组:A组(吡罗昔康)、B组(EMLA乳膏)、C组(安慰剂)。数据收集工具是一份由三部分组成的问卷:人口统计信息、用于疼痛评估的视觉模拟量表(VAS)和药物可能副作用的清单。三组患者分别在干预前和干预后两个阶段评估瘘管插管时疼痛的严重程度。采用Kruscal-Wallis和Mann-Whitney统计检验及SPSS 19进行数据分析。EMLA乳膏组疼痛缓解的中位数明显高于吡罗西康组和安慰剂组,差异有统计学意义(p<0.001)。吡罗昔康与安慰剂组比较,吡罗昔康组疼痛减轻中位数明显高于安慰剂组,但差异不显著。本研究结果表明,EMLA乳膏在减轻血透患者瘘管插管引起的疼痛方面比吡罗昔康凝胶更有效。因此,根据本研究的结果,可以建议使用EMLA乳膏作为一种简单的治疗方法,可由患者自行应用,用于缓解血液透析患者瘘管插管时的疼痛。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信